SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on November 27, 2002; DOI 10.1182/blood-2002-05-1483. This Article Full Text (PDF) All Versions of this Article: 2002-05-1483v1 101/7/2476    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Levine, J. E Articles by , Search for Related Content PubMed PubMed Citation Articles by Levine, J. E Articles by , Social Bookmarking                   What's this? Submitted May 23, 2002 Accepted September 27, 2002 A Comparison of Allogeneic and Autologous Bone Marrow Transplant for Lymphoblastic Lymphoma John E Levine, Richard E Harris, Fausto R Loberiza, Jr, James O Armitage, Julie M Vose, Koen Van Besien, Hillard M Lazarus, Mary M Horowitz*, and University of Michigan, Ann Arbor, Michigan, USA Children's Hospital Medical Center, Cincinnati, Ohio, USA IBMTR, Medical College of Wisconsin, Milwaukee, Wisconsin, USA University of Nebraska Medical Center, Omaha, Nebraska, USA University of Chicago, Chicago, Illinois, USA Case Western Reserve University, Cleveland, Ohio, USA * Corresponding author; email: marymh{at}mcw.edu. Lymphoblastic lymphoma (LBL) is a rare, clinically aggressive neoplasm of the young that frequently involves the bone marrow (BM) and/or central nervous system. Because LBL is similar to acute lymphoblastic leukemia, some centers prefer allogeneic hematopoietic stem cell transplantation (SCT) over autologous SCT. We retrospectively analyzed outcomes for patients who underwent autologous (auto, N=128) or HLA-identical sibling (allo, N=76) SCT from 1989 to 1998 and were reported to IBMTR or ABMTR. AlloSCT recipients had higher treatment-related mortality (TRM) at 6 months (18% vs 3%, p=0.002) and this disadvantage persisted at 1 and 5 years. Early relapse rates after allo and autoSCT were similar, but significantly lower relapse rates were observed in alloSCT recipients at 1 and 5 years (32% vs 46%, p=0.05; and 34% vs 56%, p=0.004, respectively). No differences were noted in lymphoma-free survival rates between the allo and autoSCT (5-year rates 36% vs 39%, p=0.82). AutoSCT recipients had higher overall survival at 6 months (75% vs 59%, p=0.01), but survival did not significantly differ between the 2 groups at 1 and 5 years (60% vs 49, p=0.09; 44% vs 39%, p=0.47, respectively). Multivariate analyses to account for confounding factors confirmed these results. Independent of SCT type, BM involvement at the time of transplant and disease status more advanced than CR1 were associated with inferior outcomes. In summary, alloSCT for LBL is associated with fewer relapses than compared to autoSCT, but higher TRM offsets any potential survival benefit. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Hunault, M. Truchan-Graczyk, D. Caillot, J.-L. Harousseau, S. Bologna, C. Himberlin, D. Guyotat, C. Berthou, P. Casassus, L. Baranger, et al. Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial Haematologica, December 1, 2007; 92(12): 1623 - 1630. [Abstract] [Full Text] [PDF] K. Song, M. Barnett, R. Gascoyne, M Chhanabhai, D. Forrest, D. Hogge, J. Lavoie, S. Nantel, T. Nevill, J. Shepherd, et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes Ann. Onc., March 1, 2007; 18(3): 535 - 540. [Abstract] [Full Text] [PDF] W. Stock and N. L. Seibel Acute lymphoblastic leukemia and lymphoblastic lymphoma ASH Self-Assessment Program, January 1, 2007; 2007(1): 253 - 264. [Full Text] [PDF] S.-W. Kim, T. E. Tanimoto, N. Hirabayashi, S. Goto, M. Kami, S. Yoshioka, T. Uchida, K. Kishi, Y. Tanaka, A. Kohno, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan Blood, July 1, 2006; 108(1): 382 - 389. [Abstract] [Full Text] [PDF] B. V. Duwe, D. H. Sterman, and A. I. Musani Tumors of the Mediastinum Chest, October 1, 2005; 128(4): 2893 - 2909. [Abstract] [Full Text] [PDF] A. K. Ganti, P. J. Bierman, J. C. Lynch, R. G. Bociek, J. M. Vose, and J. O. Armitage Hematopoietic stem cell transplantation in mantle cell lymphoma Ann. Onc., April 1, 2005; 16(4): 618 - 624. [Abstract] [Full Text] [PDF] K. K. Ballen and R. P. Hasserjian Case 15-2004 - A 31-Year-Old Man with Bilateral Testicular Enlargement N. Engl. J. Med., May 13, 2004; 350(20): 2081 - 2087. [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020